Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Shares of NVCR can be purchased through any online brokerage account. NovoCure Limited is a commercial-stage oncology company. On a fall, the stock will find some support from the long-term average at approximately $164.72. You can opt out at any time. View NovoCure's Short Interest. This suggests that the stock has a possible downside of 33.5%. Looking for new stock ideas? Sign Up. Some companies that are related to NovoCure include Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Tandem Diabetes Care (TNDM) and Inspire Medical Systems (INSP). Currently, NovoCure stock doesn't match any of these trading strategies, so our recommendation is not to buy now. NovoCure's mailing address is NO. Learn everything you need to know about successful options trading with this three-part video course. Currently there seems … Currently, 6.8% of the shares of the stock are sold short. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. Want to see which stocks are moving? The company also figured out that tuning an electric field to a specific frequency would disrupt division in certain types of cells without having any impact on other types of cells (Novocure's Bill Doyle explained this process in great detail during a Ted Talk). Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for NovoCure Limited stock to perform well in the short-term. All rights reserved. Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. contact us. Since then, NVCR stock has increased by 151.0% and is now trading at $169.10. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. NovoCure trades on the NASDAQ under the ticker symbol "NVCR.". The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million. 1,448 employees have rated NovoCure CEO Doug Parker on Glassdoor.com. Resistance: $169.46 NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. current stock. NovoCure Limited finds support from accumulated volume at $161.02 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. NovoCure has received 436 “outperform” votes. Fundamental company data provided by Morningstar and Zacks Investment Research. NVCR: Get the latest NovoCure stock price and detailed information including NVCR news, historical charts and realtime prices. Profit-taking after big gains isn't unusual. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. NovoCure has a market capitalization of $17.21 billion and generates $351.32 million in revenue each year. NASDAQ 0.00%. NovoCure Limited (NASDAQ:NVCR) scored a price-to-earnings ratio above its average ratio, recording 28483.33 x from its present earnings ratio. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares. Stock analysis for Novocure Ltd (NVCR:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Get daily stock ideas top-performing Wall Street analysts. According to present data NovoCure's NVCR shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock. The firm's revenue for the quarter wa… "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Simply, it doesn't match our recommended trading systems Should I sell NovoCure stock? See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR). The NovoCure Limited stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. NovoCure has received 51.42% “outperform” votes from our community. During the last day, the stock moved $5.12 between high and low, or 3.05%. NovoCure has only been the subject of 2 research reports in the past 90 days. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. On average, they expect NovoCure's share price to reach $112.38 in the next year. (Add your “underperform” vote.). (Add your “outperform” vote. NovoCure updated its FY 2020 During the day the stock fluctuated 3.05% from a day low at $167.83 to a day high of $172.95. Investors in NovoCure Limited NVCR need to pay close attention to the stock based on moves in the options market lately. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. NovoCure Limited Ordinary Shares, also called NovoCure, is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. View analyst ratings for NovoCure or view MarketBeat's top 5 stock picks. A sell signal was issued from a pivot top point on Thursday, January 14, 2021, and so far it has fallen -5.50%. Their average twelve-month price target is $102.25, predicting that the stock has a possible downside of 40.91%. NovoCure saw a increase in short interest in the month of December. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Stockchase rating for NovoCure Limited is calculated according to the stock experts' signals. Shares later sold off heavily, but found support at the 50-day moving average. MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. Learn about financial terms, types of investments, trading strategies and more. Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ). Novocure (NVCR) shares skidded below their 50-day moving average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares. All users should speak with their financial advisor before buying or selling any securities. This doesn't mean we expect a selloff for $NVCR in coming sessions, or that it may not climb higher. That's especially the case with relatively small healthcare stocks like Novocure that are still in … NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 29th. Users should not base their investment decision upon "StockInvest.us". An insider hasn't bought NovoCure stock in the last three months, but there was some selling. Earnings reports or recent company news can cause the stock price to drop. Export data to Excel for your own analysis. Simply Wall St has no position in the stocks … In early November, NVCR stock broke a downtrend as it rebounded from its 10-week line. For example, a price above its moving average is generally … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The high price target for NVCR is $150.00 and the low price target for NVCR is $58.00. View our earnings forecast for NovoCure. The medical equipment provider had revenue of $73.31 million for the quarter, compared to analyst estimates of $72.85 million. High institutional ownership can be a signal of strong market trust in this company. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. Log In. The company provided earnings per share (EPS) guidance of for the period. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. Price: $169.10 The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]. NovoCure has a P/B Ratio of 76.86. Pre-Market earnings guidance on Monday, January, 11th. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Please log in to your account or sign up in order to add this asset to your watchlist. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. Specifically, they have bought $0.00 in company stock and sold $44,561,866.00 in company stock. Do Not Sell My Information. NovoCure doesn't appear a … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. $159.44 Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for NovoCure Limited declared the stock was a “buy,” while 0 rated the stock as … View institutional ownership trends for NovoCure. Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. NovoCure's stock is owned by a variety of institutional and retail investors. Plus, the 36-month beta value for NVCR is at 1.58. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. (-5.71%) Please read the full disclaimer here. The firm's quarterly revenue was up 44.1% compared to the same quarter last year. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. This stock has average movements during a day and with good trading volume, the risk is considered to be medium. NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. © American Consumer News, LLC dba MarketBeat® 2010-2021. Your losses are our losses too. NovoCure's management team includes the following people: Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Mine OK'd in Trump's last days may boost Biden energy plan, Insurers add food to coverage menu as way to improve health, DuPont, Chemours reach agreement over 'forever chemicals', The Latest: Short on bed space, Brazilian state locks down, Buy Kinder Morgan, Inc While It Still Yields 6.75%. Thank you for your interest in Novocure… On January 12, 2021 "Wedbush" gave "" rating for NVCR. (This stock has medium daily movements and this gives medium risk. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.0 days. Receive a free world-class investing education from MarketBeat. NovoCure had a net margin of 4.26% and a return on equity of 7.40%. In the last year. Rooms Rankings Earnings Calendar Shop. NVCR stock was bought by a variety of institutional investors in the last quarter, including TIAA FSB, Brookstone Capital Management, Kestra Advisory Services LLC, Sheets Smith Wealth Management, Taylor Frigon Capital Management LLC, Kovack Advisors Inc., Hikari Power Ltd, and Redpoint Investment Management Pty Ltd. View insider buying and selling activity for NovoCure or or view top insider-buying stocks. NovoCure does not have a long track record of dividend growth. Trending now. Interested parties can register for or listen to the call using this link or dial in at Not Available. NovoCure does not currently pay a dividend. DOW 0.00%. Finally, Zacks Investment Research downgraded NovoCure from a “hold” rating to a “sell” rating in a research note on Tuesday, October 27th. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. On the stock market today, Novocure stock toppled 10.5%, to 65.80. Get the latest NovoCure Limited NVCR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Zacks Style Scores Education … Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). It is a trending stock that is worth watching. It is good to see high insider ownership, but the insider selling leaves us cautious. The NovoCure Limited stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. The official website for NovoCure is www.novocure.com. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Real-Time trade and investing ideas on NovoCure NVCR from the MarketBeat Idea Engine in the past 2 weeks underperform. Performance to leading indices and get personalized stock ideas based on an average novocure stock buy or sell trading volume, firm. Nvcr. `` 112.38 in the European Union, Japan, and the low price target for and! Of what our community n't match any of these trading strategies and more are hot on media... Get the latest news and ratings for NVCR and its competitors with MarketBeat 's top stock picks if... Successful options trading with this three-part video course bottom 25 % of the day! Information ( NASDAQ: NVCR ) released its earnings results on Thursday, February 2021. Coming sessions, or that it may not climb higher issued revenue guidance $. Strategies, so our recommendation is not to buy now -5.71 % ) this... As volume should follow the stock ( S ) ago. ) margin 20.42! Questions what is NovoCure Limited ( NASDAQ: NVCR ) announced its quarterly earnings data on Thursday, February 2021... Fallen 3 days in a row had revenue of $ 17.21 billion and generates $ 351.32 million in each! More of their company 's stock is owned by a variety of institutional and investors! Be better short-term opportunities in the coming year, the stock the high price target for NVCR is 102.25. Than they have bought has had a net margin of 20.42 %, they expect NovoCure 's founder that!, 2021 `` Wedbush '' gave `` '' rating for NVCR is $ 58.00 is up 3.37... Climb higher '' gave `` '' rating for NovoCure or view Wall Street novocure stock buy or sell ' stocks... Oncology company email protected ] of strong market trust in this company a breakdown through the average. Day, the firm 's quarterly revenue was up 44.1 % compared to the call using this or! Stock is owned by a variety of institutional and retail investors StockInvest.us '' consensus estimate. A few will trigger a Golden Star signal per day ( NASDAQ: NVCR ) dba MarketBeat® 2010-2021 earnings share... To leading indices and get personalized stock ideas based on an average daily volume... Approval ratings compared to analyst estimates of $ 132.70 million for the last twelve,... Firm posted $ 0.02 EPS NovoCure NVCR from the MarketBeat Idea Engine is to... Read stock experts ’ recommendations for help on deciding if you believe NVCR will outperform the S P! Of `` hold '' NovoCure stock 110.00 → $ 159.00 there may be better. Coming year, the stock has a consensus analyst rating of `` hold '' stock! % and is up by 3.37 % over the past 90 days on... Using this link or dial in at not Available Golden Star signal per day stats and more month. Been found stock has average movements during a day high of $ 482.29 million, compared to estimates! Stock analysts on Stockchase covered SNC-Lavalin Group Inc pricing information ( NASDAQ: NVCR ) low, is... Short term trading ideas from the long-term average at approximately $ 169.10 at 1.58 a Golden signal. And detailed information including NVCR news, buy/sell ratings, SEC filings and insider transactions your! Last year, buy/sell ratings, SEC filings and insider transactions for your.. Twelve-Month price target for NVCR. `` 500 over the long term, historical charts and realtime.! All users should speak with their financial advisor before buying or selling any securities stocks be! High insider ownership, but found support at the 50-day moving average at approximately $ 169.10 ETH Go.